Natera, Inc. (NTRA)
Natera is a diagnostics company that offers blood tests for cancer, women's health and organ health. It last closed at $287.47 on Nov 17, down 0.35% on the day. NTRA last reported earnings on Thu, Nov 5, 2026. The average 12-month price target from 13 analysts is $443.31 (+54.2% from the last close), with a high of $500.00 and a low of $385.00. Analyst consensus is Strong Buy, based on the latest ratings from 13 firms (13 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 7 whale options trades in NTRA, 43% of them bullish and 57% bearish. In the past 30 days there were 10 dark pool prints totaling $16.0M, the largest $5.1M.
Key Stats
Last 12 monthsNot reported for this period.
From NTRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 13 analysts who set a price target on NTRA in the past 90 days. The average target is $443.31, with a high of $500.00 and a low of $385.00, compared with the last close of $287.47.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 9 | Baird | Maintained | Buy | $403 |
| Nov 6 | JP Morgan | Target lowered | Buy | $460 → $405 |
| Nov 6 | Evercore ISI Group | Target raised | Buy | $360 → $400 |
| Oct 27 | BTIG | Target raised | Buy | $320 → $430 |
| Oct 19 | Canaccord Genuity | Target raised | Buy | $330 → $500 |
Technical Analysis
The stock is 27% below its 20 day and 32% below its 50 day average. It is 5% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot at $287.07, and the nearest resistance the swing high (Jul 6) at $288.04.
| RSI (14) | 28.21 | Oversold below 30 | Oversold |
| MACD | -25.21 | Below its signal line | Bearish |
| Stochastic | 6.0 | Near the bottom of its range | Oversold |
| ADX (14) | 40.9 | Strong downtrend | |
| Williams %R | -93.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -119.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −26.0% | Change over 10 sessions | Bearish |
| ATR (14) | $21.94 | Typical daily range, 7.6% of price |
| RSI (14) | 44.49 | Middle of its range | Neutral |
| MACD | 25.66 | Below its signal line | Bearish |
| Stochastic | 15.4 | Near the bottom of its range | Oversold |
| ADX (14) | 39.2 | Trending down | |
| Williams %R | -93.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -66.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −12.6% | Change over 10 sessions | Bearish |
| ATR (14) | $35.48 | Typical daily range, 12.3% of price |
What happened before
See how NTRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NTRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in NTRA in the last 90 days.
Dark Pool
30DNTRA Institutional Ownership
Full report →- ▲515 buying vs 392 selling
- ▼Held by funds -1.2 pts
- ▲Funds holding +91
- ▼Superinvestors: 1 added, 7 cut
- ▼Put/call 0.15 to 3.16
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 943 | 852 | +10.7% |
| In funds' top 10 | 27 | 21 | +28.6% |
| Held by funds | 93.8% | 94.9% | −1.2 pts |
| New / increased | 183 / 332 | 154 / 358 | +0.6% |
| Reduced / sold out | 305 / 87 | 242 / 68 | +26.5% |
| Put/call ratio | 3.16 | 0.15 | +1992.1% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTRA is in one of them and how their past NTRA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NTRA in an article yet. Here's the latest on the wider market.
NTRA Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Buy | $1K – $15K | Jul 17, 2026 | Sep 22, 2026 | 67 d |
| Donald J TrumpExecutive branch | Buy | $1K – $15K | May 18, 2026 | Jul 1, 2026 | 44 d |
| Donald J TrumpExecutive branch | Buy | $1K – $15K | May 15, 2026 | Jul 1, 2026 | 47 d |
| Donald J TrumpExecutive branch | Sell | $1K – $15K | Mar 17, 2026 | May 14, 2026 | 58 d |
| Donald J TrumpExecutive branch | Other | $1K – $15K | Feb 19, 2026 | May 14, 2026 | 84 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Natera
Natera is a diagnostics company based in Austin, Texas, that uses blood tests built on genetic analysis to guide medical decisions. Its tests cover cancer, including Signatera, which tracks disease that may remain or return after treatment, women's health, including prenatal and hereditary cancer screening, and organ health, including transplant rejection and kidney disease. The company sells its tests directly in the United States and through laboratory partners worldwide, serving physicians, patients and cancer researchers.
- Headquarters
- Austin, TX
- Founded
- 2004
- Website
- natera.com ↗






